Literature DB >> 16376102

Regulatory T cells in immune surveillance and treatment of cancer.

Tomoyuki Yamaguchi1, Shimon Sakaguchi.   

Abstract

Naturally occurring CD25(+)CD4(+) regulatory T cells (T(R) cells), which specifically express the transcription factor Foxp3, engage in the maintenance of immunological self-tolerance and suppressive control of aberrant or excessive immune responses to foreign antigens. They may, on the other hand, impede immune surveillance against cancer and hamper the development of effective immunity to autologous tumor cells. Indeed, natural T(R) cells have been observed to predominantly infiltrate tumor masses especially in the early phase of tumor progression. Depletion of natural T(R) cells by removing CD25(+) T cells prior to tumor challenge is therefore able to provoke effective tumor immunity in animals. Furthermore, attenuation of T(R) cell-mediated suppression in on-going anti-tumor immune responses, for example by altering signaling through CTLA-4 or GITR expressed by natural T(R) cells, can enhance the responses and thereby eradicate advanced cancers. A combination of depletion or attenuation of T(R) cells and concomitant stimulation of effector T cells, systemically or locally in tumors, may be a feasible immunotherapy for cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16376102     DOI: 10.1016/j.semcancer.2005.11.005

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  74 in total

1.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

Review 2.  Role for urinary biomarkers in diagnosis of acute rejection in the transplanted kidney.

Authors:  Basma Merhi; George Bayliss; Reginald Y Gohh
Journal:  World J Transplant       Date:  2015-12-24

Review 3.  A review of the importance of immune responses in luminal B breast cancer.

Authors:  Delia J Nelson; Briony Clark; Kylie Munyard; Vincent Williams; David Groth; Jespal Gill; Henry Preston; Arlene Chan
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

4.  T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine.

Authors:  Moses K Donkor; Abira Sarkar; Peter A Savage; Ruth A Franklin; Linda K Johnson; Achim A Jungbluth; James P Allison; Ming O Li
Journal:  Immunity       Date:  2011-07-14       Impact factor: 31.745

5.  A major role for Bim in regulatory T cell homeostasis.

Authors:  Claire A Chougnet; Pulak Tripathi; Celine S Lages; Jana Raynor; Allyson Sholl; Pamela Fink; David R Plas; David A Hildeman
Journal:  J Immunol       Date:  2010-11-22       Impact factor: 5.422

6.  Analysis of circulating regulatory T cells (CD4+CD25+CD127-) after cryosurgery in prostate cancer.

Authors:  Tong-Guo Si; Jun-Ping Wang; Zhi Guo
Journal:  Asian J Androl       Date:  2013-06-03       Impact factor: 3.285

Review 7.  Foxp3+ regulatory T cells: differentiation, specification, subphenotypes.

Authors:  Markus Feuerer; Jonathan A Hill; Diane Mathis; Christophe Benoist
Journal:  Nat Immunol       Date:  2009-07       Impact factor: 25.606

8.  Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance.

Authors:  Xuefang Cao; Karen Leonard; Lynne I Collins; Sheng F Cai; Joshua C Mayer; Jacqueline E Payton; Michael J Walter; David Piwnica-Worms; Robert D Schreiber; Timothy J Ley
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 9.  Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Authors:  Celalettin Ustun; Jeffrey S Miller; David H Munn; Daniel J Weisdorf; Bruce R Blazar
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

10.  Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.

Authors:  Paulo Cesar Maciag; Matthew M Seavey; Zhen-Kun Pan; Soldano Ferrone; Yvonne Paterson
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.